Twist Bioscience Corp. has established a drug discovery agreement with Ono Pharmaceutical Co. Ltd. to discover and develop novel antibodies for the treatment of autoimmune diseases.

Serengen GmbH and Deargen Inc. have established a collaboration to accelerate the drug discovery process by bringing together Serengen’s novel DNA encoded library (DEL) technology with Deargen’s artificial intelligence (AI)-driven drug discovery platform, Deardti.

CCM Biosciences Inc. has launched with a focus on discovering and developing novel drugs, including small molecules, gene therapies, biologics and nanomedicines, and companion diagnostic tests.

KRAS-mutated tumors were once untreatable. In fact, KRAS was something of a poster child for so-called undruggability. Several laboratories are investigating strategies to address other mutations and uses beyond non-small cell lung cancer (NSCLC) and colorectal cancer. If you can't bind KRAS to block it, use a glue or combine multiple weapons. This is the idea behind two new approaches that target cancers caused by this proto-oncogene.

Peptigrowth Inc. and Orizuru Therapeutics Inc. have entered into a joint development agreement to create a novel synthetic peptide that will replace a recombinant growth factor used in the manufacturing of a regenerative medicine product being developed by Orizuru.

3Z ehf and Biotx.ai AG have established a strategic partnership to help advance the development of drugs for attention deficit hyperactivity disorder (ADHD).

Chiesi Global Rare Diseases, a Chiesi Farmaceutici SpA business unit, has signed a co-development agreement with Aliada Therapeutics Inc.

Alexion, Astrazeneca Rare Disease, part of Astrazeneca plc, has entered a definitive purchase and license agreement for a portfolio of preclinical gene therapy programs and enabling technologies from Pfizer Inc.

An mRNA vaccine candidate that acts in the liver by recruiting memory T cells could be the key against malaria, according to a study in mice that demonstrated its efficacy by including a natural killer T (NKT) cell agonist.